Report of the Task Force on the Availability of Cardiovascular Drugs to the Medically Indigent.

Executive Summary ................................................ 850 Summary of Findings ............................................... 850 Recommendations ............................................... 850 Introduction ............................................... 850 Cardiovascular Disease Prevalence and Cost ................................................ 851 Prevalence ............................................... 851 Cost ............................................... 852 Demographics ............................................... 852 The Insured ............................................... 852 The Uninsured ............................................... 852 The Underinsured ............................................... 852 Lack of Access to Medical Care ......... ...................................... 852 Lack of Access to Medications ............................................... 853 Plans for Universal Access to Medical Care by Other Countries .......... ............ 853 Proposed US Programs ............................................... 853 US Programs Providing Access to Medication ............................................... 853 Community Programs ............................................... 853 State Programs ............................................... 855 Pharmaceutical Companies ............................................... 858